Index RUT
P/E -
EPS (ttm) -2.38
Insider Own 28.66%
Shs Outstand 45.92M
Perf Week 5.42%
Market Cap 618.14M
Forward P/E -
EPS next Y -2.52
Insider Trans -19.99%
Shs Float 37.18M
Perf Month -12.15%
Income -104.70M
PEG -
EPS next Q -0.61
Inst Own 56.13%
Short Float 14.88%
Perf Quarter 125.48%
Sales 8.78M
P/S 70.40
EPS this Y 3.09%
Inst Trans -1.96%
Short Ratio 4.52
Perf Half Y 242.77%
Book/sh 3.47
P/B 3.41
EPS next Y -9.33%
ROA -43.23%
Short Interest 5.53M
Perf Year 35.70%
Cash/sh 3.86
P/C 3.07
EPS next 5Y -
ROE -60.80%
52W Range 3.35 - 16.40
Perf YTD 125.48%
Dividend Est. -
P/FCF -
EPS past 5Y -44.06%
ROI -63.71%
52W High -27.68%
Beta 0.79
Dividend TTM -
Quick Ratio 6.99
Sales past 5Y -5.84%
Gross Margin 46.15%
52W Low 254.03%
ATR (14) 1.12
Dividend Ex-Date -
Current Ratio 6.99
EPS Y/Y TTM 8.51%
Oper. Margin -1307.05%
RSI (14) 55.31
Volatility 8.25% 8.95%
Employees 110
Debt/Eq 0.04
Sales Y/Y TTM -29.21%
Profit Margin -1192.34%
Recom 1.22
Target Price 22.29
Option/Short Yes / Yes
LT Debt/Eq 0.03
EPS Q/Q 7.84%
Payout -
Rel Volume 0.76
Prev Close 12.41
Sales Surprise -23.54%
EPS Surprise 1.41%
Sales Q/Q -14.29%
Earnings Mar 25 AMC
Avg Volume 1.22M
Price 11.86
SMA20 -4.10%
SMA50 27.96%
SMA200 93.00%
Trades
Volume 936,133
Change -4.43%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-26-24 Upgrade
TD Cowen
Market Perform → Outperform
Nov-20-23 Resumed
JP Morgan
Neutral
Jul-25-23 Downgrade
TD Cowen
Outperform → Market Perform
May-01-23 Upgrade
BofA Securities
Underperform → Neutral
$9 → $12
Apr-26-23 Resumed
Canaccord Genuity
Buy
$24
Jan-06-23 Downgrade
BofA Securities
Buy → Underperform
$22 → $9
Oct-24-22 Upgrade
SVB Leerink
Mkt Perform → Outperform
$30
Jan-31-22 Initiated
Jefferies
Buy
$50
Dec-03-21 Initiated
BofA Securities
Buy
$43
Nov-22-21 Upgrade
JP Morgan
Neutral → Overweight
$41
May-18-21 Initiated
UBS
Neutral
$35
May-10-21 Upgrade
Wedbush
Neutral → Outperform
Apr-26-21 Resumed
Credit Suisse
Outperform
$58
Feb-10-21 Downgrade
Wedbush
Outperform → Neutral
Dec-15-20 Resumed
H.C. Wainwright
Buy
$70
Dec-11-20 Reiterated
Needham
Buy
$48 → $56
Oct-23-20 Initiated
Cantor Fitzgerald
Overweight
$49
Sep-29-20 Resumed
JP Morgan
Neutral
$34
Sep-29-20 Initiated
Needham
Buy
$42
Dec-18-19 Initiated
Wedbush
Outperform
$31
Show Previous Ratings
Apr-29-24 10:21AM
08:00AM
Apr-25-24 10:01AM
Apr-23-24 07:45AM
Apr-17-24 08:00AM
04:30PM
Loading…
Apr-04-24 04:30PM
Mar-27-24 11:40PM
08:50AM
Mar-26-24 04:07PM
11:20AM
07:54AM
07:49AM
Mar-25-24 09:53PM
05:10PM
04:01PM
04:01PM
Loading…
04:01PM
Feb-29-24 08:50AM
Feb-26-24 10:00AM
Feb-25-24 01:37PM
Feb-19-24 02:31PM
Feb-15-24 09:55AM
06:59AM
Jan-17-24 04:30PM
Jan-08-24 08:00AM
Jan-04-24 04:30PM
Jan-02-24 10:29AM
(Yahoo Finance Video) +11.41%
Dec-14-23 09:55AM
Dec-01-23 09:00AM
Nov-21-23 08:00AM
Nov-09-23 05:48AM
07:00AM
Loading…
Nov-07-23 07:00AM
Oct-17-23 04:30PM
Sep-21-23 08:00AM
Sep-20-23 04:30PM
Sep-05-23 07:00AM
Aug-16-23 01:00PM
Aug-08-23 06:02AM
Aug-07-23 08:15AM
07:00AM
Aug-02-23 08:00AM
Jul-25-23 02:32PM
07:00AM
Jul-21-23 07:30AM
Jul-05-23 01:20PM
Jun-21-23 04:22AM
Jun-16-23 04:30PM
Jun-14-23 09:55AM
May-09-23 09:55AM
06:04AM
May-06-23 08:03AM
May-04-23 10:00AM
08:55AM
07:00AM
May-03-23 08:00AM
May-02-23 10:02AM
Apr-25-23 07:00AM
Mar-28-23 10:40AM
Mar-15-23 07:00AM
Mar-06-23 08:15AM
07:00AM
Feb-27-23 04:30PM
Feb-07-23 08:00AM
Jan-26-23 05:59AM
Jan-09-23 08:00AM
Jan-04-23 08:00AM
Dec-02-22 09:00AM
Nov-29-22 07:30AM
Nov-14-22 01:02PM
08:25AM
07:00AM
Nov-10-22 08:32AM
07:30AM
Nov-07-22 09:55AM
Oct-19-22 10:02AM
Aug-25-22 07:30AM
Aug-19-22 06:40AM
Aug-10-22 09:55AM
Aug-09-22 11:54AM
Aug-08-22 08:15AM
07:00AM
Jun-01-22 02:00PM
(American City Business Journals)
07:30AM
May-12-22 07:44AM
May-10-22 07:00AM
May-05-22 10:06AM
May-02-22 04:35PM
Apr-07-22 07:30AM
Apr-05-22 07:30AM
Mar-10-22 07:00AM
Mar-01-22 09:43AM
Feb-28-22 10:00AM
07:30AM
Feb-10-22 10:00AM
Jan-13-22 11:13AM
Jan-11-22 11:56AM
Jan-10-22 01:20PM
(American City Business Journals)
08:11AM
07:00AM
Jan-04-22 07:30AM
Dec-03-21 10:00AM
Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Skorpios Trust 10% Owner Apr 17 '24 Sale 11.60 3,600,000 41,760,000 10,843,681 Apr 18 04:16 PM Nash Huw M. COO & CBO Apr 01 '24 Option Exercise 0.40 50,000 20,000 61,329 Apr 03 04:19 PM Ticho Barry CHIEF MEDICAL OFFICER Apr 01 '24 Option Exercise 0.60 442 265 11,911 Apr 03 04:21 PM Nash Huw M. COO & CBO Apr 01 '24 Sale 13.23 61,329 811,212 0 Apr 03 04:19 PM Ticho Barry CHIEF MEDICAL OFFICER Apr 01 '24 Sale 13.23 9,426 124,684 2,485 Apr 03 04:21 PM Allan Jonathan GENERAL COUNSEL & CORP SEC Mar 28 '24 Sale 13.20 5,126 67,668 2,598 Apr 01 04:14 PM Kaye Edward M. MD CEO Mar 19 '24 Sale 6.10 11,150 67,999 69,350 Mar 19 08:30 PM Tulipano Stephen J CFO Mar 19 '24 Sale 6.10 4,116 25,102 20,746 Mar 19 08:36 PM Ticho Barry CHIEF MEDICAL OFFICER Mar 19 '24 Sale 6.10 4,116 25,102 11,469 Mar 19 08:34 PM Nash Huw M. COO & CBO Mar 19 '24 Sale 6.10 4,116 25,102 11,329 Mar 19 08:31 PM Allan Jonathan GENERAL COUNSEL & CORP SEC Mar 19 '24 Sale 6.10 2,349 14,326 7,724 Mar 19 08:29 PM Ticho Barry CHIEF MEDICAL OFFICER Mar 15 '24 Option Exercise 0.00 13,100 0 15,585 Mar 19 08:34 PM Tulipano Stephen J CFO Mar 15 '24 Option Exercise 0.00 13,100 0 24,862 Mar 19 08:36 PM Nash Huw M. COO & CBO Mar 15 '24 Option Exercise 0.00 13,100 0 15,445 Mar 19 08:31 PM Kaye Edward M. MD CEO Mar 15 '24 Option Exercise 0.00 35,500 0 80,500 Mar 19 08:30 PM Allan Jonathan GENERAL COUNSEL & CORP SEC Mar 15 '24 Option Exercise 0.00 7,475 0 10,073 Mar 19 08:29 PM Ticho Barry CHIEF MEDICAL OFFICER Mar 01 '24 Option Exercise 0.60 5,504 3,302 12,485 Mar 05 04:21 PM Ticho Barry CHIEF MEDICAL OFFICER Mar 01 '24 Sale 7.75 10,000 77,469 2,485 Mar 05 04:21 PM TZIANABOS ARTHUR Director Feb 13 '24 Option Exercise 2.19 31,739 69,508 31,739 Feb 15 04:17 PM Ticho Barry CHIEF MEDICAL OFFICER Feb 01 '24 Sale 4.80 10,000 47,991 6,981 Feb 05 04:32 PM Ticho Barry Chief Medical Officer Jan 02 '24 Sale 5.74 10,000 57,352 16,981 Jan 04 04:38 PM Ticho Barry Chief Medical Officer Jul 03 '23 Sale 10.60 15,000 158,973 25,895 Jul 06 05:20 PM Allan Jonathan General Counsel & Corp Sec Jun 21 '23 Sale 13.48 1,948 26,252 0 Jun 23 04:45 PM Ticho Barry Chief Medical Officer Jun 01 '23 Sale 11.13 15,000 166,964 40,895 Jun 05 07:31 PM Ticho Barry Chief Medical Officer May 04 '23 Sale 10.00 653 6,530 55,895 May 08 07:35 PM Ticho Barry Chief Medical Officer May 03 '23 Sale 10.14 24,697 250,366 56,548 May 03 08:04 PM Ticho Barry Chief Medical Officer May 02 '23 Sale 10.00 5,513 55,134 81,245 May 03 08:04 PM Ticho Barry Chief Medical Officer May 01 '23 Sale 10.00 24,967 249,767 86,758 May 03 08:04 PM
Index RUT
P/E -
EPS (ttm) -5.45
Insider Own 3.28%
Shs Outstand 101.64M
Perf Week -5.67%
Market Cap 6.54B
Forward P/E -
EPS next Y -3.28
Insider Trans -6.77%
Shs Float 101.15M
Perf Month -10.81%
Income -526.24M
PEG -
EPS next Q -1.14
Inst Own 108.26%
Short Float 13.88%
Perf Quarter -21.83%
Sales 7.53M
P/S 868.44
EPS this Y 18.23%
Inst Trans -1.40%
Short Ratio 6.97
Perf Half Y 92.93%
Book/sh -3.80
P/B -
EPS next Y 26.51%
ROA -57.23%
Short Interest 14.04M
Perf Year 65.16%
Cash/sh 5.88
P/C 10.63
EPS next 5Y 15.00%
ROE -
52W Range 25.98 - 110.25
Perf YTD -25.10%
Dividend Est. -
P/FCF -
EPS past 5Y -22.79%
ROI -154.11%
52W High -43.28%
Beta 0.71
Dividend TTM -
Quick Ratio 6.12
Sales past 5Y 12.30%
Gross Margin -82.78%
52W Low 140.69%
ATR (14) 2.93
Dividend Ex-Date -
Current Ratio 6.12
EPS Y/Y TTM -28.21%
Oper. Margin -6589.71%
RSI (14) 34.86
Volatility 3.40% 4.04%
Employees 423
Debt/Eq -
Sales Y/Y TTM -92.04%
Profit Margin -6988.63%
Recom 1.44
Target Price 96.06
Option/Short Yes / Yes
LT Debt/Eq -
EPS Q/Q 4.77%
Payout -
Rel Volume 0.63
Prev Close 65.34
Sales Surprise -78.05%
EPS Surprise -43.97%
Sales Q/Q -14.56%
Earnings May 08 AMC
Avg Volume 2.01M
Price 62.53
SMA20 -10.25%
SMA50 -10.77%
SMA200 22.02%
Trades
Volume 1,286,291
Change -4.30%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-24-24 Downgrade
UBS
Buy → Neutral
$61 → $92
Jan-05-24 Downgrade
Morgan Stanley
Overweight → Equal-Weight
$60 → $90
Nov-09-23 Initiated
Goldman
Buy
$50
Nov-07-23 Initiated
B. Riley Securities
Buy
$66
Aug-15-23 Initiated
SVB Securities
Outperform
$58
Feb-17-23 Initiated
BofA Securities
Neutral
$49
Dec-23-22 Reiterated
Needham
Buy
$60 → $58
Dec-20-22 Initiated
Truist
Buy
$60
Oct-11-22 Initiated
UBS
Buy
$80
Jan-28-22 Initiated
Goldman
Buy
$74
Dec-22-21 Initiated
Oppenheimer
Outperform
$55
Dec-10-21 Initiated
JP Morgan
Overweight
$58
Oct-07-21 Initiated
Jefferies
Buy
$75
Mar-12-21 Initiated
Wolfe Research
Outperform
$50
Feb-18-21 Initiated
Barclays
Overweight
$28
Jan-20-21 Reiterated
H.C. Wainwright
Buy
$22 → $41
Oct-29-20 Initiated
Goldman
Neutral
$16
Jul-10-20 Initiated
Raymond James
Strong Buy
$39
May-05-20 Initiated
Mizuho
Buy
$31
Apr-09-20 Upgrade
Morgan Stanley
Equal-Weight → Overweight
$25
Show Previous Ratings
Apr-29-24 04:00PM
Apr-26-24 04:44PM
06:00AM
Apr-24-24 04:00PM
Apr-10-24 09:27AM
07:30AM
Loading…
07:30AM
Apr-09-24 07:00PM
Apr-05-24 07:30AM
Apr-02-24 04:00PM
Apr-01-24 04:00PM
Mar-25-24 08:15AM
Mar-20-24 08:30AM
Mar-18-24 08:01PM
Mar-17-24 08:50AM
Mar-13-24 02:25PM
06:46AM
Loading…
Mar-12-24 06:46AM
(Thomson Reuters StreetEvents)
Mar-04-24 04:00PM
Mar-01-24 06:47PM
04:00PM
Feb-29-24 07:30AM
Feb-28-24 10:27AM
(FierceBiotech.com) -9.75%
10:22AM
07:30AM
Feb-27-24 05:10PM
04:42PM
04:17PM
(Associated Press Finance)
04:00PM
Feb-13-24 04:00PM
Feb-12-24 12:38AM
Feb-09-24 10:01AM
(Investor's Business Daily)
09:10AM
Loading…
Feb-08-24 09:10AM
Feb-06-24 04:00PM
Feb-05-24 05:30PM
(The Wall Street Journal)
Jan-29-24 07:30AM
Jan-25-24 07:30AM
Jan-18-24 01:00PM
Jan-12-24 04:40PM
02:47PM
01:07PM
05:27AM
Jan-11-24 04:22PM
04:05PM
12:58PM
(The Wall Street Journal)
12:54PM
12:47PM
(The Wall Street Journal)
12:30PM
Jan-10-24 01:04PM
Jan-09-24 01:17PM
Jan-08-24 05:14PM
(The Wall Street Journal) +15.29%
04:42PM
(Investor's Business Daily)
02:12PM
(Investor's Business Daily)
01:11PM
(The Wall Street Journal)
01:05PM
Jan-03-24 04:00PM
06:45AM
Jan-02-24 04:00PM
Dec-29-23 01:01PM
Dec-28-23 03:09PM
(Investor's Business Daily)
02:43PM
09:44AM
Dec-27-23 05:26PM
(Yahoo Finance Video) +82.54%
03:52PM
01:59PM
01:00PM
12:21PM
(Associated Press Finance)
09:41AM
08:34AM
07:39AM
07:32AM
07:30AM
Dec-26-23 04:00PM
Dec-15-23 10:22AM
Dec-07-23 07:30AM
Dec-01-23 04:00PM
Nov-29-23 04:00PM
Nov-10-23 03:04PM
Nov-04-23 12:16PM
Nov-03-23 04:00PM
11:43AM
(Thomson Reuters StreetEvents)
11:20AM
Nov-02-23 06:59PM
05:25PM
04:24PM
(Associated Press Finance)
04:00PM
09:55AM
Nov-01-23 04:00PM
Oct-31-23 02:24PM
12:43PM
Oct-26-23 09:08PM
Oct-23-23 04:00PM
Oct-19-23 07:30AM
Oct-09-23 07:53AM
Oct-06-23 12:45PM
Oct-05-23 04:00PM
Oct-03-23 04:00PM
Oct-02-23 04:00PM
Sep-28-23 07:30AM
Sep-15-23 01:05AM
Sep-14-23 01:02AM
Sep-09-23 03:59PM
Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
HENDERSON JOHN T Director Apr 25 '24 Sale 64.54 10,562 681,671 32,070 Apr 25 06:54 PM Malik Fady Ibraham EVP Research & Development Apr 09 '24 Option Exercise 6.67 28,605 190,795 171,172 Apr 09 04:38 PM Malik Fady Ibraham EVP Research & Development Apr 09 '24 Sale 74.31 32,605 2,422,918 138,567 Apr 09 04:38 PM Malik Fady Ibraham EVP Research & Development Mar 05 '24 Option Exercise 6.67 28,604 190,789 167,577 Mar 05 04:05 PM Malik Fady Ibraham EVP Research & Development Mar 05 '24 Sale 67.56 32,604 2,202,606 138,973 Mar 05 04:05 PM HENDERSON JOHN T Director Feb 14 '24 Option Exercise 4.44 5,000 22,200 47,632 Feb 14 04:04 PM HENDERSON JOHN T Director Feb 14 '24 Sale 76.48 5,000 382,400 42,632 Feb 14 04:04 PM Blum Robert I President & CEO Feb 13 '24 Option Exercise 6.67 12,500 83,375 454,297 Feb 13 04:01 PM Blum Robert I President & CEO Feb 13 '24 Sale 76.85 12,500 960,625 441,797 Feb 13 04:01 PM Malik Fady Ibraham EVP Research & Development Feb 06 '24 Option Exercise 6.67 28,605 190,795 175,578 Feb 06 04:43 PM Malik Fady Ibraham EVP Research & Development Feb 06 '24 Sale 79.30 32,605 2,585,496 142,973 Feb 06 04:43 PM Blum Robert I President & CEO Jan 31 '24 Option Exercise 6.67 12,500 83,375 454,297 Feb 02 04:41 PM Blum Robert I President & CEO Jan 31 '24 Sale 79.57 12,500 994,625 441,797 Feb 02 04:41 PM Blum Robert I President & CEO Jan 19 '24 Option Exercise 6.67 12,500 83,375 454,297 Jan 22 05:19 PM Blum Robert I President & CEO Jan 19 '24 Sale 81.42 12,500 1,017,750 441,797 Jan 22 05:19 PM HENDERSON JOHN T Director Jan 12 '24 Option Exercise 4.44 5,000 22,200 47,632 Jan 12 05:20 PM HENDERSON JOHN T Director Jan 12 '24 Sale 85.14 5,000 425,700 42,632 Jan 12 05:20 PM Malik Fady Ibraham EVP Research & Development Jan 04 '24 Option Exercise 7.96 11,678 92,957 162,651 Jan 04 04:36 PM Malik Fady Ibraham EVP Research & Development Jan 04 '24 Sale 86.98 15,678 1,363,712 146,973 Jan 04 04:36 PM Blum Robert I President & CEO Jan 02 '24 Option Exercise 6.67 12,500 83,375 454,297 Jan 02 05:55 PM Blum Robert I President & CEO Jan 02 '24 Sale 85.08 12,500 1,063,500 441,797 Jan 02 05:55 PM WIERENGA WENDALL Director Dec 27 '23 Option Exercise 4.44 10,000 44,400 23,653 Dec 27 04:11 PM WIERENGA WENDALL Director Dec 27 '23 Sale 73.60 10,000 736,000 18,653 Dec 27 04:11 PM HENDERSON JOHN T Director Dec 18 '23 Option Exercise 6.72 13,020 87,494 44,838 Dec 19 04:12 PM Blum Robert I President & CEO Dec 18 '23 Option Exercise 6.67 12,500 83,375 454,297 Dec 19 04:13 PM Blum Robert I President & CEO Dec 18 '23 Sale 36.95 12,500 461,875 441,797 Dec 19 04:13 PM HENDERSON JOHN T Director Dec 18 '23 Sale 36.34 2,458 89,324 42,380 Dec 19 04:12 PM Blum Robert I President & CEO Nov 30 '23 Option Exercise 6.67 12,500 83,375 453,917 Dec 01 04:15 PM Blum Robert I President & CEO Nov 30 '23 Sale 32.99 12,500 412,375 441,417 Dec 01 04:15 PM Blum Robert I President & CEO Nov 15 '23 Option Exercise 6.67 12,500 83,375 453,917 Nov 15 05:22 PM Blum Robert I President & CEO Nov 15 '23 Sale 34.57 12,500 432,125 441,417 Nov 15 05:22 PM Malik Fady Ibraham EVP Research & Development Nov 09 '23 Sale 35.40 2,500 88,500 150,664 Nov 09 04:35 PM Blum Robert I President & CEO Oct 30 '23 Option Exercise 6.67 12,500 83,375 453,917 Oct 30 04:02 PM Blum Robert I President & CEO Oct 30 '23 Sale 32.17 12,500 402,125 441,417 Oct 30 04:02 PM Blum Robert I President & CEO Oct 16 '23 Option Exercise 6.67 12,500 83,375 453,917 Oct 16 05:57 PM Blum Robert I President & CEO Oct 16 '23 Sale 33.70 12,500 421,250 441,417 Oct 16 05:57 PM Malik Fady Ibraham EVP Research & Development Oct 12 '23 Sale 35.89 2,500 89,725 153,164 Oct 12 06:39 PM Blum Robert I President & CEO Oct 06 '23 Option Exercise 6.67 12,500 83,375 453,917 Oct 06 04:52 PM Blum Robert I President & CEO Oct 06 '23 Sale 30.00 12,500 375,000 441,417 Oct 06 04:52 PM Malik Fady Ibraham EVP Research & Development Sep 14 '23 Sale 34.86 2,500 87,150 155,664 Sep 14 04:09 PM Blum Robert I President & CEO Sep 13 '23 Option Exercise 6.67 12,500 83,375 453,917 Sep 13 04:09 PM Blum Robert I President & CEO Sep 13 '23 Sale 34.90 12,500 436,206 441,417 Sep 13 04:09 PM Blum Robert I President & CEO Aug 25 '23 Option Exercise 7.70 12,500 96,275 453,917 Aug 28 06:45 PM Blum Robert I President & CEO Aug 25 '23 Sale 33.99 12,500 424,875 441,417 Aug 28 06:45 PM WIERENGA WENDALL Director Aug 21 '23 Option Exercise 6.72 6,020 40,454 24,225 Aug 21 04:01 PM WIERENGA WENDALL Director Aug 21 '23 Sale 32.02 6,020 192,760 18,205 Aug 21 04:01 PM Blum Robert I President & CEO Aug 11 '23 Option Exercise 9.54 12,500 119,287 453,125 Aug 11 04:18 PM Blum Robert I President & CEO Aug 11 '23 Sale 32.37 12,500 404,589 441,417 Aug 11 04:18 PM Malik Fady Ibraham EVP Research & Development Aug 10 '23 Sale 31.70 2,500 79,250 158,164 Aug 10 04:14 PM Blum Robert I President & CEO Aug 01 '23 Option Exercise 9.65 12,500 120,625 452,108 Aug 01 04:57 PM Blum Robert I President & CEO Aug 01 '23 Sale 32.63 12,500 407,856 441,417 Aug 01 04:57 PM Blum Robert I President & CEO Jul 13 '23 Option Exercise 9.65 12,500 120,625 453,917 Jul 13 04:10 PM Blum Robert I President & CEO Jul 13 '23 Sale 35.28 12,500 440,940 441,417 Jul 13 04:10 PM Malik Fady Ibraham EVP Research & Development Jul 13 '23 Sale 35.37 2,500 88,425 160,664 Jul 13 04:09 PM Bhanji Muna Director Jul 07 '23 Sale 34.12 2,000 68,235 14,031 Jul 07 04:17 PM Blum Robert I President & CEO Jul 03 '23 Option Exercise 9.65 12,500 120,625 453,917 Jul 05 04:18 PM Blum Robert I President & CEO Jul 03 '23 Sale 32.60 12,500 407,500 441,417 Jul 05 04:18 PM Blum Robert I President & CEO Jun 12 '23 Option Exercise 9.65 12,500 120,625 453,917 Jun 12 05:49 PM Blum Robert I President & CEO Jun 12 '23 Sale 37.06 12,500 463,250 441,417 Jun 12 05:49 PM Malik Fady Ibraham EVP Research & Development Jun 08 '23 Sale 38.07 2,500 95,175 163,164 Jun 08 04:31 PM Blum Robert I President & CEO May 31 '23 Option Exercise 9.65 12,500 120,625 453,558 Jun 01 05:06 PM Blum Robert I President & CEO May 31 '23 Sale 37.67 12,500 470,875 441,058 Jun 01 05:06 PM Blum Robert I President & CEO May 16 '23 Option Exercise 9.65 12,500 120,625 453,558 May 16 04:33 PM Blum Robert I President & CEO May 16 '23 Sale 37.41 12,500 467,625 441,058 May 16 04:33 PM HENDERSON JOHN T Director May 15 '23 Option Exercise 6.78 4,166 28,245 29,586 May 15 04:07 PM HENDERSON JOHN T Director May 15 '23 Sale 37.77 4,166 157,350 25,420 May 15 04:07 PM Malik Fady Ibraham EVP Research & Development May 11 '23 Sale 39.50 1,787 70,586 165,396 May 11 05:26 PM Malik Fady Ibraham EVP Research & Development May 03 '23 Option Exercise 7.96 7,000 55,720 174,183 May 03 04:46 PM Malik Fady Ibraham EVP Research & Development May 03 '23 Sale 40.00 7,000 280,000 167,183 May 03 04:46 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite